Home » Stocks » Heron Therapeutics

Heron Therapeutics, Inc. (HRTX)

Stock Price: $15.53 USD -0.51 (-3.18%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.41B
Revenue (ttm) 139.77M
Net Income (ttm) -193.32M
Shares Out 90.64M
EPS (ttm) -2.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $15.53
Previous Close $16.04
Change ($) -0.51
Change (%) -3.18%
Day's Open 16.26
Day's Range 15.32 - 16.44
Day's Volume 2,275,731
52-Week Range 9.60 - 26.81

More Stats

Market Cap 1.41B
Enterprise Value 1.08B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 90.64M
Float 84.49M
EPS (basic) -2.27
EPS (diluted) -2.28
FCF / Share -1.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 17.05M
Short Ratio 16.36
Short % of Float 22.32%
Beta 1.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10.07
PB Ratio 4.96
Revenue 139.77M
Operating Income -198.73M
Net Income -193.32M
Free Cash Flow -116.45M
Net Cash 330.95M
Net Cash / Share 3.65
Gross Margin -59.41%
Operating Margin -142.19%
Profit Margin -138.30%
FCF Margin -83.32%
ROA -27.16%
ROE -55.45%
ROIC -66.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 10
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$31.40*
(102.19% upside)
Low
19.0
Current: 15.53
High
70.0
Target: 31.40
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue14677.4730.771.28----0.651.30
Revenue Growth88.41%151.81%2305.55%------50.35%-
Gross Profit84.3549.9626.181.24----0.651.30
Operating Income-211-184-195-171-96.81-75.48-54.46-23.83-11.06-9.93
Net Income-205-179-197-173-97.59-76.37-55.28-23.35-11.81-7.35
Shares Outstanding81.7873.1954.0437.9333.0826.5716.1612.226.011.98
Earnings Per Share-2.50-2.44-3.65-4.56-2.95-2.87-3.42-1.91-1.96-3.70
Operating Cash Flow-125-192-170-134-78.53-60.28-40.76-17.01-7.72-5.48
Capital Expenditures-7.15-9.15-2.48-3.14-0.85-1.44-1.69-0.97-0.51-0.08
Free Cash Flow-132-201-173-137-79.37-61.72-42.45-17.98-8.23-5.56
Cash & Equivalents39133217251.1413172.6872.2953.5117.972.11
Total Debt19.794.5728.6852.912.221.601.030.490.10-
Net Cash / Debt371328144-1.7712971.0871.2653.0117.872.11
Assets51346223467.4813876.6875.9455.9719.452.91
Liabilities10992.0210388.7319.7413.626.994.153.691.60
Book Value404370131-21.2511863.0668.9551.8215.751.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Heron Therapeutics, Inc.
Country United States
Employees 231
CEO Barry D. Quart

Stock Information

Ticker Symbol HRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HRTX
IPO Date August 26, 1987

Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.